Global Tumor Necrosis Factor Inhibitors Drug Market Dosage Price and Clinical Pipeline Outlook 2024

Download Sample

 

For Report Sample Contact: neeraj@kuickresearch.com

 

Report Weblink: https://www.kuickresearch.com/report-global-tumor-necrosis-factor-inhibitors-drug-market-dosage-price-and-clinical-pipeline-outlook-2024.php

 

Table of Contents

 

1. Tumor Necrosis Factor :  An Overview

  1.1 Prologue to Tumor Necrosis Factor

  1.2 History and Discovery of Tumor Necrosis Factors

2. Significance of Tumor Necrosis Factor

  2.1 TNF in Cell Signaling and Immunity

    2.1.1 Tumor Necrosis Factor Receptor 1

    2.1.2 Tumor Necrosis Factor Receptor 2

  2.2 Role of TNF in Cancer

  2.3 Disease Related to TNF and Members of Its Family

3. Working Mechanism of Tumor Necrosis Factors (TNF) Inhibitors and Their Therapeutic Evolution

  3.1 Tumor Necrosis Factor and Immune Response

  3.2 Tumor Necrosis Factor Inhibition by Monoclonal Antibodies

4. Approaches Used in Development of TNF Inhibitors

  4.1 Monoclonal Antibody Approach

  4.2 Recombinant DNA Technology Approach

5. Global Tumor Necrosis Factor Alpha Inhibitors Pipeline Overview

6. Global Tumor Necrosis Factor Alpha Inhibitors Clinical Pipeline by Company, Indication and Phase

  6.1 Unknown

  6.2 Research

  6.3 Preclinical

  6.4 Clinical

  6.5 Phase-I

  6.6 Phase-I/II

  6.7 Phase-II

  6.8 Phase-II/III

  6.9 Phase-III

  6.10 Preregistration

  6.11 Registered

7. Marketed Global Tumor Necrosis Factor Alpha Inhibitors Clinical Insight by Company and Indication

  7.1 Golimumab (Shinponi, Simponi, Simponi Aria, Simponi I.V, Sympony and Symposony)

  7.2 Pomalidomide (Imnovid and Pomalyst)

  7.3 Adalimumab (Humira and Raheara)

  7.4 Infliximab (Remicade)

  7.5 Certolizumab Pegol (CIMZIA AutoClicks Prefilled Pen, Cimzia and Simziya)

  7.6 Apremilast (Otezla)

  7.7 Infliximab Biosimilar – Celltrion

  7.8 Lumbricus Rubellus Extract (Inflectra and Remsima)

  7.9 Adalimumab Biosimilar (AdaliRel and Adfrar)

  7.10 Infliximab Biosimilar (Infimab)

  7.11 Infliximab Biosimilar – Bionovis/ The Instituto Vital Brazil

  7.12 Adalimumab Biosimilar (Exemptia)

  7.13 Anti-Tumour Necrosis Factor-Alpha Antibody Oral

8. Price, Dosage and Treatment Cost Analysis of Commercially Available TNF Based Therapeutics

  8.1 Cimzia (Certolizumab Pegol)

  8.2 Enbrel (Etanercept)

    8.2.1 Benepali andndash; Etanercept Biosimilar

  8.3 Humira ( Adalimumab)

    8.3.1 Amjevita andndash; Humira Biosimilar

    8.3.2 Cyltezo andndash; Second Biosimilar to Humira

  8.4 Otezla (Apremilast)

  8.5 Remicade (Infliximab)

    8.5.1 Remsima – Infliximab Biosimilar

    8.5.2 Inflectra andndash; Infliximab Biosimilar

  8.6 Simponi (Golimumab)

9. Current Market Trends and Recent Advances in the TNF Inhibitors Segment

  9.1 Dominance of TNF Inhibitors in Global Therapeutics Market

  9.2 Global TNF Inhibitor Market by Indication andndash; Market Size and Growing Opportunity

    9.2.1 Rheumatoid Arthritis

    9.2.2 Psoriasis and psoriatic arthritis (PsA)

    9.2.3 Crohn’s Disease

    9.2.4 Ankylosing Spondylitis

  9.3 Global TNF Inhibitors Market by Region

    9.3.1 US

    9.3.2 Europe

    9.3.3 Asia- Pacific

    9.3.4 Middle East and Africa (MEA)

10. TNF Inhibitor- Sales and Patent Analysis

  10.1 TNF Inhibitor Market by Sales

    10.1.1 Cimzia

    10.1.2 Enbrel

    10.1.3 Humira

    10.1.4 Remicade

  10.2 TNF Inhibitor Market by Approvals and Patent

  10.3 TNF Inhibitor Biosimilar Sales Analysis

11. TNF Inhibitors Market Driving Parameters

12. Restraining Factors of the Global TNF Inhibitors Market

13. Global  TNF Inhibitors Future Forecast and Sales Projections

  13.1 Impact of Biosimilar ‘Benepali’ on Enbrel Sales

  13.2 Affordable Alternatives to Humira and Their Effect on Global Humira Sales

  13.3 Remicade and Its Biosimilar

  13.4 Conclusion and Executive Summary

14. Competitive Landscape

  14.1 AbbVie

  14.2 Ablynx

  14.3 Apogenix

  14.4 AryoGen Biopharma

  14.5 Bionovis

  14.6 CASI Pharmaceuticals

  14.7 Celltrion

  14.8 Celgene Corporation

  14.9 Delenex Therapeutics

  14.10 Dexa Medica

  14.11 EPIRUS Biopharmaceuticals

  14.12 Janssen Biotech

  14.13 GlaxoSmithKline

  14.14 HanAll Biopharma

  14.15 Intas Pharmaceuticals

  14.16 LEO Pharma

  14.17 LG Life Sciences

  14.18 MedImmune

  14.19 Momenta Pharmaceuticals

  14.20 Novartis

  14.21 PROBIOMED

  14.22 Reliance Life Sciences

  14.23 Sandoz

  14.24 Samsung Bioepis

  14.25 Sanofi-Aventis

  14.26 Shanghai CP Guojian Pharmaceutical

  14.27 Shanghai Pharmaceuticals

  14.28 Simcere Pharmaceutical

  14.29 Toyama Chemical

  14.30 Tsumura

  14.31 UCB

  14.32 Zydus Cadila

 

 

Figure 1-1: Multiple Roles of TNF

Figure 1-2: Historical timeline of Tumor Necrosis Factor

Figure 1-3: Historical Timeline of Tumor Necrosis Factor Inhibitors

Figure 2-1: TNF Factor Types and Their Inhibition

Figure 2-2: Diseases Related to TNF and Its Family Members

Figure 3-1: General Working Mechanism of TNF Inhibitors

Figure 5-1: Global Tumor Necrosis Factor Alpha Inhibitors Pipeline by Phase (%), 2018 till 2024

Figure 5-2: Global Tumor Necrosis Factor Alpha Inhibitors Pipeline by Phase (Number), 2018 till 2024

Figure 5-3: Global Tumor Necrosis Factor Alpha Inhibitors Pipeline by Phase (%),2018 till 2024

Figure 5-4: Global Tumor Necrosis Factor Alpha Inhibitors Pipeline by Phase (Number), 2018 till 2024

Figure 8-1: Cimzia – Dose for Crohn’s Disease (mg/week)

Figure 8-2: Cimzia – Dose for Rheumatoid Arthritis (US$)

Figure 8-3: Cimzia – Dose for Psoriatic Arthritis (mg)

Figure 8-4: Cimzia – Dose for Ankolysing Spondylitis (mg)

Figure 8-5: Cimzia (Certolizumab Pegol) andndash; Average Price (US$)

Figure 8-6: Cimzia – Treatment Cost Analysis, 2018

Figure 8-7: TNF inhibition by Enbrel, Working Mechanism

Figure 8-8: Enbrel – Dosage Forms and Strength (mg and ml)

Figure 8-9: Enbrel – Dosage and Frequency for Arthritis, AS and PsA (mg/Week)

Figure 8-10: Enbrel – Dose for Juvenile Idiopathic Arthritis (mg and mg/kg)

Figure 8-11: Enbrel – Subcutaneous Kit Price (US$/Unit), 2018

Figure 8-12: Enbrel – Prefilled Syringe Price (US$/Vial), 2018

Figure 8-13: Global – Enbrel Price by Region (US$)

Figure 8-14: Enbrel – Treatment Cost Analysis (US$/Month)

Figure 8-15: Enbrel – Price per QALY Gained (US$), 2018

Figure 8-16: Humira – Mechanism of Action

Figure 8-17: Humira – Dosage Analysis by Indication (mg)

Figure 8-18: Humira – Dosage Analysis for Crohn’s Disease (mg)

Figure 8-19: Humira andndash; Dose for Plaque Psoriasis (mg)

Figure 8-20: Humira – Subcutaneous Kit Price (US$), 2017

Figure 8-21: Humira – Average Treatment Cost Analysis per Month (US$), 2017

Figure 8-22: Otezla – Dose for Plaque Psoriasis

Figure 8-23: Otezla – Price Analysis (US$/Unit), 2017

Figure 8-24: Remicade (Infliximab)- Mode of Action

Figure 8-25: Remicade – Dose for Crohn’s Disease (mg/kg)

Figure 8-26: Remicade – Dose for Rheumatoid Arthritis (mg/kg)

Figure 8-27: Remicade- Price Analysis for 100mg Vial (US$), 2018

Figure 8-28: Simponi – Availability by Concentration (mg/0.5ml)

Figure 8-29: Simponi – Dosage Analysis (mg)

Figure 8-30: Simponi – Price Analysis (US$/ml), 2018

Figure 9-1: Global- Therapeutics Market Segmentation by size (%)

Figure 9-2: Global – Rheumatoid Arthritis Prevalence (per 100,000 Individuals), 2016-2017

Figure 9-3: Global – Psoriasis and Psoriatic Arthritis Prevalence, 2015-2016

Figure 9-4: Global- Crohn’s Disease Epidemiology (per 100,000 Individuals), 2012-2017

Figure 9-5: Global – Ankylosing Spondylitis (per 100,000 Individuals), 2018

Figure 9-6: US – TNF inhibitors Market by Prevalence of Indication (per 1000 Individuals) , 2017

Figure 9-7: Humira Cost Analysis by Region- US v/s India (US$/Vial), 2017

Figure 10-1: Global- Cimzia Sales (US$ Million), 2016 and 2017

Figure 10-2: Global – Enbrel Sales (US$ Million), 2014-2017

Figure 10-3: Global- Humira Sales (US$ Million), 2014-2017

Figure 10-4: Global- Remicade Sales (US$ Million), 2014-2017

Figure 10-5: Global – TNF Inhibitors Patent by Number

Figure 10-6: Patent Analysis – Patent Expiration by Year

Figure 10-7: Global – TNF Inhibitor Biosimilar Sales (US$ Million), 2015-2017

Figure 10-8: Global – Benepali Sales (US$ Million), 2016-2017

Figure 11-1: Driving Factors of the TNF Inhibitors Segment

Figure 12-1: Challenging Factors of the TNF Inhibitors Market

Figure 13-1: Global andndash; Enbrel Sales Future Forecast (US$ Million), 2017-2024

Figure 13-2: Global – Humira Sales Forecast (US$ Million), 2017-2024

Figure 13-3: Global – Amjevita Sales Future Forecast (US$ Million), 2020 and 2024

Figure 13-4: Global – Remicade Future Sales Forecast (US$ Million), 2016-2024

Figure 13-5: Global – Blockbuster TNF Inhibitors Sales (US$ Billion), 2017

Figure 14-1: Ablynx – Clinical Pipeline

Figure 14-2: Apogenix – Clinical Pipeline

Figure 14-3: Casi Pharmaceutical – Clinical Pipeline

Figure 14-4: Celgene – Clinical Pipeline

Figure 14-5: EPIRUS Biopharmaceuticals – Clinical Pipeline

Figure 14-6: HanAll Biopharma – Clinical Pipeline

Figure 14-7: Novartis – Clinical Pipeline

Figure 14-8: Sandoz – Clinical Pipeline

Figure 14-9: Toyama Chemical – Clinical Pipeline

Figure 14-10: Zydus Cadila – Clinical Pipeline